rs761546902
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_014140.4(SMARCAL1):c.863-2A>G variant causes a splice acceptor, intron change. The variant allele was found at a frequency of 0.0000509 in 1,612,504 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000051 ( 0 hom. )
Consequence
SMARCAL1
NM_014140.4 splice_acceptor, intron
NM_014140.4 splice_acceptor, intron
Scores
5
1
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 6.27
Genes affected
SMARCAL1 (HGNC:11102): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a like 1) The protein encoded by this gene is a member of the SWI/SNF family of proteins. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein shows sequence similarity to the E. coli RNA polymerase-binding protein HepA. Mutations in this gene are a cause of Schimke immunoosseous dysplasia (SIOD), an autosomal recessive disorder with the diagnostic features of spondyloepiphyseal dysplasia, renal dysfunction, and T-cell immunodeficiency. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.08132635 fraction of the gene. Cryptic splice site detected, with MaxEntScore 6.6, offset of 38, new splice context is: tccccacggtcaacctgcAGcct. Cryptic site results in frameshift change. If cryptic site found is not functional and variant results in exon loss, it results in inframe change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-216420297-A-G is Pathogenic according to our data. Variant chr2-216420297-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 562358.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-216420297-A-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCAL1 | NM_014140.4 | c.863-2A>G | splice_acceptor_variant, intron_variant | ENST00000357276.9 | NP_054859.2 | |||
SMARCAL1 | NM_001127207.2 | c.863-2A>G | splice_acceptor_variant, intron_variant | NP_001120679.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCAL1 | ENST00000357276.9 | c.863-2A>G | splice_acceptor_variant, intron_variant | 2 | NM_014140.4 | ENSP00000349823.4 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152070Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
8
AN:
152070
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000120 AC: 30AN: 250252Hom.: 0 AF XY: 0.000140 AC XY: 19AN XY: 135320
GnomAD3 exomes
AF:
AC:
30
AN:
250252
Hom.:
AF XY:
AC XY:
19
AN XY:
135320
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000507 AC: 74AN: 1460434Hom.: 0 Cov.: 31 AF XY: 0.0000619 AC XY: 45AN XY: 726602
GnomAD4 exome
AF:
AC:
74
AN:
1460434
Hom.:
Cov.:
31
AF XY:
AC XY:
45
AN XY:
726602
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152070Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74282
GnomAD4 genome
AF:
AC:
8
AN:
152070
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74282
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
10
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Schimke immuno-osseous dysplasia Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 11, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 11, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 06, 2024 | This sequence change affects an acceptor splice site in intron 4 of the SMARCAL1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SMARCAL1 are known to be pathogenic (PMID: 11799392, 20301550). This variant is present in population databases (rs761546902, gnomAD 0.3%). Disruption of this splice site has been observed in individual(s) with Schimke immuno-osseous dysplasia (PMID: 11799392, 22998683). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 562358). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on SMARCAL1 function (PMID: 22998683). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, no assertion criteria provided | research | Gharavi Laboratory, Columbia University | Sep 16, 2018 | - - |
SMARCAL1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 21, 2022 | The SMARCAL1 c.863-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. In the literature this variant is also reported as IVS4-2A>G. This variant has been reported in the compound heterozygous and homozygous states in individuals with Schimke immuno-osseous dysplasia (Boerkoel et al. 2002. PubMed ID: 11799392; Dekel et al. 2008. PubMed ID: 18356746; Morimoto et al. 2012. PubMed ID: 22998683). Of note, other splicing variants impacting c.863 have also been reported as causative (Boerkoel et al. 2002. PubMed ID: 11799392). This variant is reported in 0.26% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-217285020-A-G). Variants that disrupt the consensus splice acceptor site in SMARCAL1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: 2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at